Neurodegenerative Diseases Therapeutics Market, Global Outlook and Forecast 2022-2028

May 2022 | 61 pages | ID: NE67272D8C5CEN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Neurodegenerative Diseases Therapeutics in Global, including the following market information:

Global Neurodegenerative Diseases Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Neurodegenerative Diseases Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Multiple Sclerosis Therapeutics Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Neurodegenerative Diseases Therapeutics include AB Science SA, AbbVie Inc., Acadia Pharmaceuticals Inc., Biogen Inc., F. Hoffmann La Roche Ltd., H Lundbeck AS, Mitsubishi Chemical Holdings Corp., Novartis AG and Sanofi and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Neurodegenerative Diseases Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Neurodegenerative Diseases Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Neurodegenerative Diseases Therapeutics Market Segment Percentages, by Type, 2021 (%)

• Multiple Sclerosis Therapeutics
• Alzheimer's Disease Therapeutics
• Parkinson's Disease Therapeutics
• Parkinson's Disease Therapeutics
• Others

Global Neurodegenerative Diseases Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Neurodegenerative Diseases Therapeutics Market Segment Percentages, by Application, 2021 (%)

• Child
• Aldult

Global Neurodegenerative Diseases Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Neurodegenerative Diseases Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Neurodegenerative Diseases Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Neurodegenerative Diseases Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• AB Science SA
• AbbVie Inc.
• Acadia Pharmaceuticals Inc.
• Biogen Inc.
• F. Hoffmann La Roche Ltd.
• H Lundbeck AS
• Mitsubishi Chemical Holdings Corp.
• Novartis AG
• Sanofi
• Teva Pharmaceutical Industries Ltd

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Neurodegenerative Diseases Therapeutics Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Neurodegenerative Diseases Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL NEURODEGENERATIVE DISEASES THERAPEUTICS OVERALL MARKET SIZE

2.1 Global Neurodegenerative Diseases Therapeutics Market Size: 2021 VS 2028
2.2 Global Neurodegenerative Diseases Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Neurodegenerative Diseases Therapeutics Players in Global Market
3.2 Top Global Neurodegenerative Diseases Therapeutics Companies Ranked by Revenue
3.3 Global Neurodegenerative Diseases Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Neurodegenerative Diseases Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Neurodegenerative Diseases Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Neurodegenerative Diseases Therapeutics Players in Global Market
  3.6.1 List of Global Tier 1 Neurodegenerative Diseases Therapeutics Companies
  3.6.2 List of Global Tier 2 and Tier 3 Neurodegenerative Diseases Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Neurodegenerative Diseases Therapeutics Market Size Markets, 2021 & 2028
  4.1.2 Multiple Sclerosis Therapeutics
  4.1.3 Alzheimer's Disease Therapeutics
  4.1.4 Parkinson's Disease Therapeutics
  4.1.5 Parkinson's Disease Therapeutics
  4.1.6 Others
4.2 By Type - Global Neurodegenerative Diseases Therapeutics Revenue & Forecasts
  4.2.1 By Type - Global Neurodegenerative Diseases Therapeutics Revenue, 2017-2022
  4.2.2 By Type - Global Neurodegenerative Diseases Therapeutics Revenue, 2023-2028
  4.2.3 By Type - Global Neurodegenerative Diseases Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Neurodegenerative Diseases Therapeutics Market Size, 2021 & 2028
  5.1.2 Child
  5.1.3 Aldult
5.2 By Application - Global Neurodegenerative Diseases Therapeutics Revenue & Forecasts
  5.2.1 By Application - Global Neurodegenerative Diseases Therapeutics Revenue, 2017-2022
  5.2.2 By Application - Global Neurodegenerative Diseases Therapeutics Revenue, 2023-2028
  5.2.3 By Application - Global Neurodegenerative Diseases Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Neurodegenerative Diseases Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Neurodegenerative Diseases Therapeutics Revenue & Forecasts
  6.2.1 By Region - Global Neurodegenerative Diseases Therapeutics Revenue, 2017-2022
  6.2.2 By Region - Global Neurodegenerative Diseases Therapeutics Revenue, 2023-2028
  6.2.3 By Region - Global Neurodegenerative Diseases Therapeutics Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Neurodegenerative Diseases Therapeutics Revenue, 2017-2028
  6.3.2 US Neurodegenerative Diseases Therapeutics Market Size, 2017-2028
  6.3.3 Canada Neurodegenerative Diseases Therapeutics Market Size, 2017-2028
  6.3.4 Mexico Neurodegenerative Diseases Therapeutics Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Neurodegenerative Diseases Therapeutics Revenue, 2017-2028
  6.4.2 Germany Neurodegenerative Diseases Therapeutics Market Size, 2017-2028
  6.4.3 France Neurodegenerative Diseases Therapeutics Market Size, 2017-2028
  6.4.4 U.K. Neurodegenerative Diseases Therapeutics Market Size, 2017-2028
  6.4.5 Italy Neurodegenerative Diseases Therapeutics Market Size, 2017-2028
  6.4.6 Russia Neurodegenerative Diseases Therapeutics Market Size, 2017-2028
  6.4.7 Nordic Countries Neurodegenerative Diseases Therapeutics Market Size, 2017-2028
  6.4.8 Benelux Neurodegenerative Diseases Therapeutics Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Neurodegenerative Diseases Therapeutics Revenue, 2017-2028
  6.5.2 China Neurodegenerative Diseases Therapeutics Market Size, 2017-2028
  6.5.3 Japan Neurodegenerative Diseases Therapeutics Market Size, 2017-2028
  6.5.4 South Korea Neurodegenerative Diseases Therapeutics Market Size, 2017-2028
  6.5.5 Southeast Asia Neurodegenerative Diseases Therapeutics Market Size, 2017-2028
  6.5.6 India Neurodegenerative Diseases Therapeutics Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Neurodegenerative Diseases Therapeutics Revenue, 2017-2028
  6.6.2 Brazil Neurodegenerative Diseases Therapeutics Market Size, 2017-2028
  6.6.3 Argentina Neurodegenerative Diseases Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Neurodegenerative Diseases Therapeutics Revenue, 2017-2028
  6.7.2 Turkey Neurodegenerative Diseases Therapeutics Market Size, 2017-2028
  6.7.3 Israel Neurodegenerative Diseases Therapeutics Market Size, 2017-2028
  6.7.4 Saudi Arabia Neurodegenerative Diseases Therapeutics Market Size, 2017-2028
  6.7.5 UAE Neurodegenerative Diseases Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 AB Science SA
  7.1.1 AB Science SA Corporate Summary
  7.1.2 AB Science SA Business Overview
  7.1.3 AB Science SA Neurodegenerative Diseases Therapeutics Major Product Offerings
  7.1.4 AB Science SA Neurodegenerative Diseases Therapeutics Revenue in Global Market (2017-2022)
  7.1.5 AB Science SA Key News
7.2 AbbVie Inc.
  7.2.1 AbbVie Inc. Corporate Summary
  7.2.2 AbbVie Inc. Business Overview
  7.2.3 AbbVie Inc. Neurodegenerative Diseases Therapeutics Major Product Offerings
  7.2.4 AbbVie Inc. Neurodegenerative Diseases Therapeutics Revenue in Global Market (2017-2022)
  7.2.5 AbbVie Inc. Key News
7.3 Acadia Pharmaceuticals Inc.
  7.3.1 Acadia Pharmaceuticals Inc. Corporate Summary
  7.3.2 Acadia Pharmaceuticals Inc. Business Overview
  7.3.3 Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Major Product Offerings
  7.3.4 Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Revenue in Global Market (2017-2022)
  7.3.5 Acadia Pharmaceuticals Inc. Key News
7.4 Biogen Inc.
  7.4.1 Biogen Inc. Corporate Summary
  7.4.2 Biogen Inc. Business Overview
  7.4.3 Biogen Inc. Neurodegenerative Diseases Therapeutics Major Product Offerings
  7.4.4 Biogen Inc. Neurodegenerative Diseases Therapeutics Revenue in Global Market (2017-2022)
  7.4.5 Biogen Inc. Key News
7.5 F. Hoffmann La Roche Ltd.
  7.5.1 F. Hoffmann La Roche Ltd. Corporate Summary
  7.5.2 F. Hoffmann La Roche Ltd. Business Overview
  7.5.3 F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Major Product Offerings
  7.5.4 F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Revenue in Global Market (2017-2022)
  7.5.5 F. Hoffmann La Roche Ltd. Key News
7.6 H Lundbeck AS
  7.6.1 H Lundbeck AS Corporate Summary
  7.6.2 H Lundbeck AS Business Overview
  7.6.3 H Lundbeck AS Neurodegenerative Diseases Therapeutics Major Product Offerings
  7.6.4 H Lundbeck AS Neurodegenerative Diseases Therapeutics Revenue in Global Market (2017-2022)
  7.6.5 H Lundbeck AS Key News
7.7 Mitsubishi Chemical Holdings Corp.
  7.7.1 Mitsubishi Chemical Holdings Corp. Corporate Summary
  7.7.2 Mitsubishi Chemical Holdings Corp. Business Overview
  7.7.3 Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Major Product Offerings
  7.7.4 Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Revenue in Global Market (2017-2022)
  7.7.5 Mitsubishi Chemical Holdings Corp. Key News
7.8 Novartis AG
  7.8.1 Novartis AG Corporate Summary
  7.8.2 Novartis AG Business Overview
  7.8.3 Novartis AG Neurodegenerative Diseases Therapeutics Major Product Offerings
  7.8.4 Novartis AG Neurodegenerative Diseases Therapeutics Revenue in Global Market (2017-2022)
  7.8.5 Novartis AG Key News
7.9 Sanofi
  7.9.1 Sanofi Corporate Summary
  7.9.2 Sanofi Business Overview
  7.9.3 Sanofi Neurodegenerative Diseases Therapeutics Major Product Offerings
  7.9.4 Sanofi Neurodegenerative Diseases Therapeutics Revenue in Global Market (2017-2022)
  7.9.5 Sanofi Key News
7.10 Teva Pharmaceutical Industries Ltd
  7.10.1 Teva Pharmaceutical Industries Ltd Corporate Summary
  7.10.2 Teva Pharmaceutical Industries Ltd Business Overview
  7.10.3 Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Major Product Offerings
  7.10.4 Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Revenue in Global Market (2017-2022)
  7.10.5 Teva Pharmaceutical Industries Ltd Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Neurodegenerative Diseases Therapeutics Market Opportunities & Trends in Global Market
Table 2. Neurodegenerative Diseases Therapeutics Market Drivers in Global Market
Table 3. Neurodegenerative Diseases Therapeutics Market Restraints in Global Market
Table 4. Key Players of Neurodegenerative Diseases Therapeutics in Global Market
Table 5. Top Neurodegenerative Diseases Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Neurodegenerative Diseases Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Neurodegenerative Diseases Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Neurodegenerative Diseases Therapeutics Product Type
Table 9. List of Global Tier 1 Neurodegenerative Diseases Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Neurodegenerative Diseases Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Neurodegenerative Diseases Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Neurodegenerative Diseases Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Neurodegenerative Diseases Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Neurodegenerative Diseases Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Neurodegenerative Diseases Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Neurodegenerative Diseases Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. AB Science SA Corporate Summary
Table 31. AB Science SA Neurodegenerative Diseases Therapeutics Product Offerings
Table 32. AB Science SA Neurodegenerative Diseases Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. AbbVie Inc. Corporate Summary
Table 34. AbbVie Inc. Neurodegenerative Diseases Therapeutics Product Offerings
Table 35. AbbVie Inc. Neurodegenerative Diseases Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. Acadia Pharmaceuticals Inc. Corporate Summary
Table 37. Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Product Offerings
Table 38. Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Biogen Inc. Corporate Summary
Table 40. Biogen Inc. Neurodegenerative Diseases Therapeutics Product Offerings
Table 41. Biogen Inc. Neurodegenerative Diseases Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. F. Hoffmann La Roche Ltd. Corporate Summary
Table 43. F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Product Offerings
Table 44. F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Revenue (US$, Mn), (2017-2022)
Table 45. H Lundbeck AS Corporate Summary
Table 46. H Lundbeck AS Neurodegenerative Diseases Therapeutics Product Offerings
Table 47. H Lundbeck AS Neurodegenerative Diseases Therapeutics Revenue (US$, Mn), (2017-2022)
Table 48. Mitsubishi Chemical Holdings Corp. Corporate Summary
Table 49. Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Product Offerings
Table 50. Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Revenue (US$, Mn), (2017-2022)
Table 51. Novartis AG Corporate Summary
Table 52. Novartis AG Neurodegenerative Diseases Therapeutics Product Offerings
Table 53. Novartis AG Neurodegenerative Diseases Therapeutics Revenue (US$, Mn), (2017-2022)
Table 54. Sanofi Corporate Summary
Table 55. Sanofi Neurodegenerative Diseases Therapeutics Product Offerings
Table 56. Sanofi Neurodegenerative Diseases Therapeutics Revenue (US$, Mn), (2017-2022)
Table 57. Teva Pharmaceutical Industries Ltd Corporate Summary
Table 58. Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Product Offerings
Table 59. Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Neurodegenerative Diseases Therapeutics Segment by Type in 2021
Figure 2. Neurodegenerative Diseases Therapeutics Segment by Application in 2021
Figure 3. Global Neurodegenerative Diseases Therapeutics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Neurodegenerative Diseases Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Neurodegenerative Diseases Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Neurodegenerative Diseases Therapeutics Revenue in 2021
Figure 8. By Type - Global Neurodegenerative Diseases Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Neurodegenerative Diseases Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Neurodegenerative Diseases Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Neurodegenerative Diseases Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Neurodegenerative Diseases Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Neurodegenerative Diseases Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Neurodegenerative Diseases Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Neurodegenerative Diseases Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Neurodegenerative Diseases Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. AB Science SA Neurodegenerative Diseases Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. AbbVie Inc. Neurodegenerative Diseases Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Biogen Inc. Neurodegenerative Diseases Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. H Lundbeck AS Neurodegenerative Diseases Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Novartis AG Neurodegenerative Diseases Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Sanofi Neurodegenerative Diseases Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)